DualityBio Raises $90 Million for Bispecific and ADC Drugs
May 20, 2021 at 05:29 AM EDT
Duality Biologics, an innovative China-US biotech company, closed a $90 million series B financing. Founded in 2020, DualityBio develops bispecific and Antibody-Drug Conjugate (ADC) drugs for oncology and autoimmune indications. It has built an internal pipeline of nearly 10 novel Best-in-Class and First-in-Class candidates, including several candidates in the IND stage. DualityBio has China operations in Shanghai and Suzhou and a US facility in Princeton . The B round was led by Lilly Asia Ventures. More details.... Share this with colleagues: // //
